Astellas Pharma US | Changing Tomorrow | Home

Previous Pause Next

Heart Health Month

At Astellas, We Are Proud to Support Heart Disease Awareness Month Read More

Peter Sandors

Astellas' Peter Sandor Reflects on Progress for Cancer Care on World Cancer Day Read More

XOSPATA Approval

XOSPATA Approved

XOSPATA® (gilteritinib) Approved by U.S. FDA for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) with a FLT3 Mutation

Learn how we're making strides against a life-threatening cancer in the latest Astellas Way Blog from Percival Barretto-Ko, President, Americas

In the Astellas Way Blog, Astellas Americas President Percival Barretto-Ko Discusses Why 2019 Will be a Pivotal Year for Our Industry Read More

1

2

3

4

News

Latest

News / Media

Feb 12, 2019

Phase 3 ARCHES Trial Shows XTANDI^® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer

News / Media

Feb 05, 2019

Astellas Announces Personnel Changes

News / Media

Jan 31, 2019

Astellas Announces Acquisition of Own Shares

News / Corporate

Feb 12, 2019

Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer

News / Corporate

Dec 20, 2018

Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI® (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer

News / Corporate

Dec 14, 2018

Astellas Acquires Potenza Therapeutics